Comparison of 48 week efficacy and safety of 400 mg QD nevirapine extended release formulation (Viramune XR) versus 200 mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada® in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE)

THLBB202

---

Time: 14:40
Speaker: Anne-Marie Quinson





For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.